Jupiter Neurosciences, Inc. (JUNS) Income Statement
JUNS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsJUNS revenue and net income
Where JUNS's revenue goes
2025Each bar shows an amount and its share of revenue. JUNS kept −39,662.8% of revenue as net income.
JUNS profit margins
JUNS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | −54.6% | −54.6% | — |
| Gross profit | — | −57.8% | −56.5% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
JUNS quarterly EPS vs estimates
Jupiter Neurosciences beat the analyst EPS estimate in 3 of the last 6 quarters. Next report: November 13, 2026.
JUNS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $21,796 | $0 | $0 | $233,281 | $638,037 | $1.1M | $0 |
| Cost of revenue | $4,231 | — | — | $0 | $0 | $0 | — |
| Gross profit | $17,565 | — | — | $233,281 | $638,037 | $1.1M | — |
| Research & development | $2.1M | $492,660 | $954,793 | $942,806 | $1.4M | $1.6M | $685,741 |
| Sales, general & admin | $6.8M | $2.6M | $2.9M | $2.7M | $3.1M | $1.3M | $1.5M |
| Total operating expenses | $8.9M | $3.1M | $3.9M | $3.7M | $4.5M | $3.0M | $2.2M |
| Operating income | −$8.9M | −$3.1M | −$3.9M | −$3.4M | −$3.9M | −$1.9M | −$2.2M |
| Interest income | $0 | $5,557 | $482 | $617 | $132 | $38 | — |
| Interest expense | $66,020 | $248,366 | $218,705 | $740,854 | $113,994 | $13,535 | $317,104 |
| Income before taxes | −$8.6M | −$2.4M | −$4.8M | −$5.0M | −$4.2M | −$1.7M | −$3.0M |
| Income taxes | — | — | — | — | $179,168 | — | — |
| Net income | −$8.6M | −$2.4M | −$4.8M | −$5.0M | −$4.4M | −$1.7M | −$3.0M |
| EBITDA | −$8.6M | −$2.2M | −$4.6M | −$4.2M | −$4.1M | −$1.6M | −$2.7M |
| EPS (diluted) | −$0.26 | −$0.07 | −$12.10 | −$39.19 | −$0.10 | −$13.99 | — |
| Gross margin | 80.6% | — | — | 100.0% | 100.0% | 100.0% | — |
| Operating margin | −40,873.2% | — | — | −1,471.4% | −612.4% | −164.4% | — |
| Net margin | −39,662.8% | — | — | −2,125.2% | −686.4% | −146.9% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24,245 | $18,652 | $21,796 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3,181 | $4,362 | — | — | $0 | $0 | — | — | — | — | — | — |
| Gross profit | $21,064 | $14,290 | — | — | $0 | $0 | — | — | — | — | — | — |
| Research & development | $600,353 | $411,049 | $43,684 | $816,697 | $759,448 | $466,745 | $201,005 | $91,911 | $101,077 | $98,667 | $244,730 | $239,458 |
| Sales, general & admin | $2.2M | $1.6M | $2.8M | $1.5M | $1.5M | $1.1M | $1.3M | $401,636 | $456,000 | $472,028 | $290,912 | $1.2M |
| Total operating expenses | $2.8M | $2.0M | $2.8M | $2.3M | $2.3M | $1.5M | $1.5M | $493,547 | $557,077 | $570,695 | $535,642 | $1.4M |
| Operating income | −$2.7M | −$2.0M | −$2.8M | −$2.3M | −$2.3M | −$1.5M | −$1.5M | −$493,547 | −$557,077 | −$570,695 | −$535,642 | −$1.4M |
| Interest income | $10,068 | $18,404 | $33,627 | $10,212 | $13,050 | $10,365 | $5,419 | $23 | $53 | $62 | $44,329 | $161 |
| Interest expense | $90,618 | $118,644 | $62,463 | $1,193 | $1,135 | $1,229 | $30,545 | $107,382 | $56,290 | $65,756 | $58,383 | $80,610 |
| Income before taxes | −$2.3M | −$2.1M | −$2.6M | −$2.3M | −$2.3M | −$1.5M | −$1.5M | −$591,021 | $313,123 | −$634,100 | −$429,645 | −$1.8M |
| Net income | −$2.3M | −$2.1M | −$2.6M | −$2.3M | −$2.3M | −$1.5M | −$1.5M | −$591,021 | $313,123 | −$634,100 | −$429,645 | −$1.8M |
| EBITDA | −$2.6M | −$1.9M | −$2.5M | −$2.3M | −$2.3M | −$1.5M | −$1.5M | −$483,639 | $369,413 | −$565,993 | −$371,262 | −$1.7M |
| EPS (diluted) | −$5.06 | −$4.39 | −$0.07 | −$0.07 | −$0.07 | −$0.05 | −$0.05 | −$0.02 | — | — | — | — |
| Gross margin | 86.9% | 76.6% | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −11,313.4% | −10,524.3% | −12,886.7% | — | — | — | — | — | — | — | — | — |
| Net margin | −9,380.9% | −11,054.9% | −11,814.2% | — | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in JUNS's financial statements (latest annual report filed April 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
JUNS financial results
In fiscal year 2025 (ended December 31, 2025), Jupiter Neurosciences reported revenue of $0.0 million. It had a net loss of $8.6 million, a net profit margin of −39,662.8%. Diluted earnings per share came to −$0.26. Over five years revenue grew at an average rate of −54.6% a year.
See the JUNS stock overview for the latest quote and news, or the JUNS chart for price history and technical indicators.
JUNS income statement FAQ
What is Jupiter Neurosciences's annual revenue?
Jupiter Neurosciences reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025.
Is Jupiter Neurosciences profitable?
No. Jupiter Neurosciences reported a net loss of $8.6 million in fiscal 2025, a net profit margin of −39,662.8%; its operating margin was −40,873.2%.
What is Jupiter Neurosciences's gross margin?
Jupiter Neurosciences's gross margin was 80.6% in fiscal 2025: for every $100 of revenue, Jupiter Neurosciences kept $81 after the direct cost of its products and services.
How much does Jupiter Neurosciences spend on research and development?
Jupiter Neurosciences spent $2.1 million on research and development in fiscal 2025, 9,573.2% of revenue.
How fast is Jupiter Neurosciences growing?
Revenue grew −54.6% a year on average over the last five fiscal years, from $1.1 million to $0.0 million.
What are Jupiter Neurosciences's earnings per share?
Jupiter Neurosciences earned $-0.26 per diluted share in fiscal 2025, compared with $-0.07 a year earlier.
When will Jupiter Neurosciences report its next earnings?
Jupiter Neurosciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Jupiter Neurosciences's fiscal year end?
Jupiter Neurosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 1, 2026.